- Recommendation ID
- TA171/1
- Question
The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide when used in people with multiple myeloma who have received two or more prior therapies.
- Any explanatory notes
(if applicable)
Source guidance details
- Comes from guidance
- Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
- Number
- TA171
- Date issued
- June 2009
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 01/06/2019 |